M&A: Page 2

Cerner acquired by Oracle for $28B

The deal further pushes Oracle into the healthcare market, where its presence is mostly in data use efficiency for payers and providers. Oracle's areas of focus include database software and cloud systems.

By Shannon Muchmore • Dec. 21, 2021

J&J device chief on company split, omicron surge, robotic surgery

Ashley McEvoy is confident that 2022 will not be as bad as the first or second year of the COVID-19 pandemic, even as the omicron variant drives cases up, but adds that "we're not out of the woods yet."

By Ricky Zipp • Dec. 20, 2021

Explore the Trendline➔

MedTech Dive Outlook 2022

The pandemic continues to disrupt the medical device industry early in 2022, as COVID-19 testing demand remains strong and nonemergent procedures are postponed. In this series, we look at the risks, challenges and opportunities ahead.

By MedTech Dive staff

Flurry of doctor group buyouts helps fuel 'extraordinary' surge in health M&A

Companies across the healthcare spectrum are pursuing deals to strengthen operations after two years of pandemic-driven challenges, a PwC report found.

By Susan Kelly • Dec. 14, 2021

Roundup: Baxter completes $10.5B Hillrom acquisition

Wall Street analysts have questioned the price and strategic fit of the deal, which is the largest medtech buy so far in 2021.

Dec. 14, 2021

New iRhythm CEO talks Medicare pricing, larger medtech competitors, international markets

"I think the near-term noise is something that we'll work through, but the underlying technology has never been questioned," Quentin Blackford told MedTech Dive.

By Ricky Zipp • Nov. 19, 2021

Stryker dismisses robotics threat from J&J, Zimmer with bullish forecast

CEO Kevin Lobo said during Thursday's analyst day that the company is "poised and ready to pounce" if valuations fall as Stryker looks to leverage M&A in long-term growth plans.

By Nick Paul Taylor • Nov. 19, 2021

Siemens Healthineers projects revenue jump fueled by Varian double-digit sales growth

The medtech expects its $16.4 billion Varian acquisition to post annual sales growth from 2023 to 2025, leading it to forecast accelerating revenue rises.

By Nick Paul Taylor • Nov. 17, 2021

Globus in takeover talks with NuVasive to boost spine portfolio: reports

Truist Securities and Piper Sandler analysts said the deal is unlikely. J.P. Morgan cautioned that earlier orthopaedic takeovers struggled to generate returns.

By Nick Paul Taylor • Nov. 16, 2021

BD's $2B annual M&A war chest, connected care devices at heart of growth plan

Evercore ISI analysts said the targets and messaging were consistent with expectations, while J.P. Morgan questioned why it is taking BD longer than its peers to return margins to pre-pandemic levels.

By Nick Paul Taylor • Nov. 15, 2021

Coloplast acquires laryngectomy device maker Atos Medical in $2.5B takeover

With Atos claiming a more than 80% share of the laryngectomy market, Coloplast sees the company as a source of growth in the coming years.

By Nick Paul Taylor • Nov. 10, 2021

Philips grows cardiac monitoring business with Cardiologs pickup

Nearly one year after announcing its $2.8 billion acquisition of BioTelemetry, the Dutch conglomerate is further expanding its reach in remote patient monitoring with the purchase of France-based Cardiologs.

By Susan Kelly • Nov. 9, 2021

4 takeaways from a bumper year of M&A medtech activity (so far)

After hunkering down last year, many companies entered 2021 with large cash reserves and acquisition targets that included players lacking scale to weather the downturn.

By Nick Paul Taylor • Oct. 11, 2021

Medtechs opened 2021 with a flurry of M&A and have not stopped spending since

With deals ranging from tuck-ins to multibillion-dollar takeovers, here's a roundup of the M&A spree so far this year after activity came to a near halt amid the unpredictability of 2020.

Oct. 7, 2021

Boston Scientific inks $1.75B deal for Baylis, biggest in string of M&A

SVB Leerink analysts wrote the acquisition will add needed support in electrophysiology and structural heart, two of the highest growth markets within cardiology. It's the medtech's fifth acquisition of 2021.

By Ricky Zipp • Oct. 6, 2021

Digital health funding shatters record again with $21.3B so far this year

This year, mental health is the top funded clinical indication with $3.1 billion raised, followed by digital health tools for managing cardiovascular disease, diabetes, primary care and oncology.

By Hailey Mensik • Oct. 5, 2021

Amid pandemic, medtech R&D, merger activity jumped: EY report

Research and development spending at pure-play medtechs rose to a level last seen before the 2007-2008 financial crisis.

By Nick Paul Taylor • Sept. 27, 2021

GE Healthcare to buy BK Medical for $1.45B

The deal is aimed at expansion beyond diagnostics into surgical and therapeutic interventions, with high-single-digit return on invested capital anticipated by year five, CEO Kieran Murphy said.

By Greg Slabodkin • Sept. 23, 2021

EU threatens Illumina for closing $8B Grail deal while still under review

The European Commission's warning of fines and other measures is another step in a saga that could run for years. If the bloc ultimately opposes the acquisition, the path forward will be through the courts.

By Nick Paul Taylor • Sept. 22, 2021

Boston Scientific to spend $269M for remaining stake of Devoro in latest deal

The medtech giant's 2021 M&A spree continues, following deals of $925 million for Preventice Solutions, $1.07 billion for Lumenis' surgical business and $295 million for cardiac ablation device maker Farapulse.

By Ricky Zipp • Sept. 21, 2021

Philip Morris takes control of Vectura amid pushback against acquisition

The tobacco giant has secured investor buy-in despite continued opposition from clinicians and reports that employees of inhaled medicine specialist Vectura are concerned about the change in ownership.

By Nick Paul Taylor • Sept. 17, 2021

Hillrom VP of connected care talks Baxter's $10.5B buy, digital health

The deal, medtech's largest of 2021, is driven by Hillrom's digital health presence. Trey Lauderdale, Hillrom vice president and general manager of care communications, says the Baxter acquisition is validation of their strategy.

By Greg Slabodkin • Sept. 16, 2021

Hong Kong-based Prenetics to go public in US as part of $1.25B SPAC merger

Prenetics, which is set to pocket $459 million through the deal, will use the money to step up its attack on markets targeted by companies including 23andMe, Exact Sciences and Invitae.

By Nick Paul Taylor • Sept. 16, 2021

Baxter's $10.5B Hillrom buy on track, deal to close by early 2022: CEO

Baxter CEO Joe Almeida said the standard U.S. antitrust waiting period expired with no second FTC information request. Other global regulatory hurdles remain and shareholders are set to vote on the deal on Dec. 2.

By Greg Slabodkin • Updated Oct. 28, 2021

Baxter in late-stage talks to buy Hillrom for about $10B: WSJ

A Baird analyst said he talked himself into backing a union given Hillrom's connected care push. However, J.P. Morgan analysts argued Baxter has a "tall order" convincing investors it's a "more strategic vs. financial" acquisition.

By Greg Slabodkin • Aug. 30, 2021

SPAC slashes value of LumiraDx merger by $2B on falling COVID-19 testing forecast

LumiraDx recently halved its full-year sales guidance after being buffeted by the same forces rocking larger COVID-19 test providers such as Abbott and Quidel.

By Nick Paul Taylor • Aug. 23, 2021